Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1200 for Advanced Solid Tumors
2023-508684-68-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- May 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 2, open-label, single-arm trial of lucansatuzumab in gastric cancer (GC), esophagogastric junction cancer, esophageal cancer and 2 more, sponsored by Merck & Co. Primary endpoints: Number of participants who experience one or more dose-limiting toxicities (DLTs), Number of participants who experience one or more adverse events (AEs) and 1 more. Started May 2024; status: completed.
02
Drugs
lucansatuzumab
03
Conditions
gastric cancer (GC)esophagogastric junction canceresophageal cancerbiliary cancerpancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2023-508684-68-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508684-68-00.